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Cancer may be one of the oldest diseases on earth. Since advances
in medicine have significantly increased our lifespan, cancer has now
become one of our biggest “natural” enemies. At the start of the “war
on cancer” 40 years ago, we had some basic misconceptions about
cancer. When Payton Rous, father of the Rous sarcoma oncovirus, won
the Nobel Prize in 1966, he criticized the concept that cancer could
be caused by somatic mutations, espousing the idea that all cancers
were caused by viruses [1,2]. As late as 1978 Isaiah Fidler, a Houston
oncologist, reported that cancer included “one cause, one mechanism
and one cure” [3]. It was just a matter of finding the right cytotoxins in
the right combination [4]. We had not yet realized that cancer could be
identified at base-pair resolutions [5]. In The Art of War [6], Sun Tzu,
who considered war a necessary evil, prophesized “Know your enemy”.
Given our present and growing knowledge of our enemy cancer, we
should not have to consider cancer a necessary evil. Since the beginning
of this millennium, we have gained a much better understanding of
this enemy. Nevertheless, we are still challenged by cancer’s limitless
replicative potential [7,8] and its seemingly illimitable power to survive,
evade, invade and metastasize.
A major problem for cancer therapy is that it exhibits hundreds
of different genotypes defined by substantial numbers of mutations in
a wide variety of genes/proteins. To simplify this diversity, Hanahan
and Weinberg [7,8] defined eight major cancer hallmarks that control
cell homeostasis and proliferation. These include self-sufficiency
in growth signals, insensitivity to growth-inhibitory (anti-growth)
signals, evasion of apoptosis, limitless replicative potential, sustained
angiogenesis, tissue invasion and metastasis, reprogramming energy
metabolism and evasion of immune surveillance. They also considered
that unstable genomes and inflammation could advance multiple
cancer hallmarks.
More recently Vogelstein et al. [5] defined a cancer genome
landscape, describing cancers as “pathway diseases” with two to
eight mutations in genes that provide selective growth advantages
to tumors referred to as “driver” mutations. These come from a class
of 12 signaling pathways that regulate three core cellular processes:
cell fate, cell survival and genome maintenance. With knowledge of
cancer’s molecular mechanisms, treatment strategies using mutationspecific, small molecule drugs or monoclonal antibodies have been
developed to specifically target some cancers as defined in cancer
hallmarks and “driver gene” pathways. One example is the treatment
of B-RAF oncoprotein, a major participant in a driver pathway in
melanoma, which provides self-sufficiency of growth signals [9,10].
However, tumors treated with B-RAF inhibitors, like other approaches
using these strategies, often develop resistance after treatment and
tumors reappear. This is a common cancer therapeutic inadequacy.
Furthermore, BRAF mutations in colorectal cancers are not responsive
to these inhibitors [11]. Thus, new treatment modalities are needed
to treat cancer, especially ones that can effectively ablate tumors
and enhance immune mechanisms. My laboratory is investigating
a relatively new therapy that modifies two cancer hallmarks without
drugs: evasion of apoptosis and sustained angiogenesis [12]; however,
the latter could be considered an anti-vascular effect. More recently,
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we have found that this novel treatment approach may also address
another cancer hallmark, evasion of immune surveillance. The
strategy, discussed below, uses pulsed power technology that delivers
nanosecond pulsed electric fields (nsPEFs) directly to tumors.
During developmental and homeostatic cell death, apoptosis is
anti-inflammatory and immunologically silent or tolerogenic [13].
Although some studies show that necrotic cells can provoke an
immune response [14-17], a number of recent studies indicate that
caspase-dependent processes are important for immunogenicity [18].
In chemotherapy-induced cell death, some (anthracyclins), but not
all (mitomycin C) caspase-inducing chemotherapeutic agents initiate
immunogenic cell death [19]; thus, not all caspase-mediated apoptosis
programs have the same impact on immune mechanisms. Apoptosis
has been shown to induce maturation of dendritic cells leading to
T-cell activation and immunity [20] and that apoptotic cells not only
undergo degradation, but also deliver processed antigen to dendritic
cells for cross-presentation [21]. Immunogenic cell death has obvious
advantages for cancer treatment. In the last several years, it has been
realized that there is a relatively specific set of cell death mechanisms
that plays roles in immunogenic cell death. These include changes in
cell surface membranes (externalized calreticulin binds to CD91 on
dendritic cells enhancing engulfment), release of soluble factors that
interact with a series of dendritic cell receptors to enhance antigen
presentation to T-cells (HMGB1 binding toll-like receptors and ATP
binding to purinergic P2RX7 stimulating IL-1β) and activation of the
immune system against cancer [18]. Thus, there is increasing evidence
that it is important to understand mechanisms of tumor cell death
because they can provide a means to enhance immune responses and
prevent recurrences through immunogenic cell death, whether by
apoptosis and/or necrosis.
The approach for in vivo cancer treatment in my laboratory and
others using nsPEFs [22-25] departs from targeting specific cancer
“drivers” with mutation-specific targeted drugs, although treatment
with nsPEFs should render most “drivers” inoperable. In evaluating
effects of nsPEFs, they do affect several cancer hallmarks as indicated
above. However, nsPEFs target the whole tumor as an organ at the
primary site.
At the first international Evolution and Cancer Conference in
June of 2011, Steven Neuberg, a social psychologist from Arizona
State University in Tempe pointed out that a more apt metaphor for
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cancer than “foreign invaders” is cancer as “criminal gangs” who as
local residence have gone bad, slowly exploit the environment around
them for their own gain. “Cancers are not outside the body, they come
from within us”, he said [26]. In this concept, the criminal gang (the
cancer) within the local community (cancer microenvironment)
coerces the local population (“educating” supporting host cells) to
use their resources (growth factors, signaling molecules) to thwart
the authorities (evading immune surveillance) and support the gang’s
criminal activity (the tumor behaving as an organ). Thus, the presence
of cancer supplies a new, demanding organ, more aggressive than
other organs in your body. Studies in my laboratory are investigating
possibilities that nsPEF ablation goes beyond eliminating tumors at the
primary site by alerting the immune system to the “criminal gang’s”
cancer activities, thereby providing a protective, vaccine-like effect and
preventing recurrences [27].
Pulsed power technology with nsPEFs ablates cancer by a nonthermal, non-drug procedure. Using pulsed power, which has been
used for decades in weaponry and high power physics, provides an
innovative progression of pulsed power to application in basic science
and cancer treatment, among other utilizations [28]. An example of
pulsed power principles inherent in nsPEFs is to compare storage of one
joule of energy released in one second (1 watt) versus released in one
microsecond (1 megawatt) or one nanosecond (1 gigawatt). The latter is
enough power to light an intermediate-sized city for that nanosecond.
The high power eliminates cells by programmed cell death. It does not
immediately “blow cells away”; cell death is delayed and mechanisms
are definable and quantifiable in vitro [29-35] and in vivo [12,27,36,37].
Cells ultimately die by programmed cell death mechanisms that include
both caspase-dependent (or -associated) and caspase-independent cell
death, which requires further characterization.
We continue to develop a local treatment modality with nsPEFs
using an orthotopic rat N1-S1 hepatocellular carcinoma (HCC)
model with the likelihood to enhance immune function [27,37].
In the world population, incidence and mortality rates of HCC are
nearly equal, symptoms and diagnoses generally occur at advanced
stages and prognoses are usually poor. Diagnoses of younger people
have increased in the US mostly due to increases in hepatitis C and B
infections. However, early diagnoses are more common due to greater
awareness, new screening approaches and high-resolution imaging
of the liver, providing more definitive diagnoses [38]. Presentation
and treatment considerations of HCC are unique compared to other
cancers because the prognosis not only depends on tumor size, but also
on underlying diseases such as cirrhosis or other hepatic functional
maladies [39]. Major problems for HCC treatment include less than
20% patient eligibility for resection because of underlying liver disease
and/or tumor position near vital structures. Furthermore, there are
no management strategies that avoid multiple treatments and prevent
recurrences. These problems are resolvable because nsPEF treatment
has sharply defined treatment zones determined by the electrode design,
which only affects tissues within electrodes surrounding the tumor.
This requires a single treatment and after ablation offers a protection
or resistance to further tumor growth [27]. It therefore appears to
vaccinate against the same cancer, thereby preventing recurrences.
There are a number of alternative treatments to surgery and
drugs with several relatively new technologies for treating HCC using
thermal approaches (radiofrequencies, microwaves, cryoablation),
chemical techniques (percutaneous ethanol / acetic acid), radiological
methods (ionizing radiation, transarterial chemoembolization and
radioembolization), high frequency ultrasound (HIFU) treatment
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and irreversible electroporation [40-45]. However, while some of
these methods have had some success, all of these most often require
multiple treatments and recurrences are common. Thermal and
chemical methods of ablation are taken from 16th century medicine
when Ambroise Pare, a self-taught “surgeon”, described charring
tumors with a coal-heated soldering iron or scorching them with
a paste of sulfuric acid [46]. Patients with HCC are generally spared
chemotherapeutic drug treatment, because HCCs are notoriously
resistant to chemotherapeutic agents and radiation. Even the new oral
multi-kinase inhibitor sorafenib for advanced HCC has only rather
modest clinical efficacy extending survival by only 7-10 months [47,48].
There are numerous advantages for using nsPEF ablation as a means
for cancer therapy as opposed to other physical and chemical methods,
radiofrequency ablation (RFA), radiation or chemotherapeutic agents.
(However, nsPEFs have been shown in combination with gemcitabine
to provide synergistic cytotoxic responses [49]). NsPEF ablation
(1) targets multiple programmed cell death mechanisms that evade
apoptosis induction and promote angiogenesis [12,36], two well-known
cancer hallmarks; (2) can induce cell death in the absence of FADD,
caspase-8 and APAF-1, which bypasses cancer-causing mutations that
block death receptor pathways and caspase activation [32]; (3) targets
mitochondria-mediated programmed cell death [30,32,50,51] even in
the presence of Bcl-xl overexpression, which protects mitochondria
[Beebe et al., unpublished]; (4) provides well-defined treatment zones
that focus treatments to the tumor and marginal tissue surrounded by
electrodes, which minimizes damage to healthy surrounding tissue
[52]; (5) exhibits broad specificity for cell death induction in tumor
masses and the microenvironment, which includes rapidly growing
tumor cells, slower growing host cells that collaborate with tumor cells
and cancer stem cells; (6) requires a single treatment lasting about
17 minutes with rapid tumor disappearance [27], which avoids long
treatment times that allow chances for resistance-causing mutations
that lead to recurrences; (7) exhibits minimal local and systemic
side effects; (8) induces local infarction of small vessels [12,36] and
transiently reduces blood flow to tumors, yet recovers to allow inflow
of immune cells [27]; and (9) provides a protective, vaccine-like effect
in ectopic mouse and orthotropic rat models for HCC [27]; this shows
that this protective effect is independent of species or tumor location.
We hypothesize that this is likely due to enhanced immune surveillance
from cells undergoing nsPEF-induced cell death, thus addressing
another cancer hallmark [27].
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